Triple-Drug cocktail targets diabetes and fatty liver in new trial
NCT ID NCT07289750
First seen Jan 04, 2026 · Last updated Jun 16, 2026 · Updated 28 times
Summary
This study tests whether adding alogliptin to a standard two-drug therapy (pioglitazone and metformin) improves blood sugar, cholesterol, and pancreas function in people with type 2 diabetes who also have fatty liver disease. About 80 adults who have not used diabetes drugs in the past six months will take part. The goal is to see if the three-drug combo works better and is safe compared to the two-drug regimen alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAFLD are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.